Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871042 | 1.00 | MAPT (0.42) | MAPTPOLBKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL4865112 | 0.80 | KDM4E (0.36) | POLBKMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL4865116 | 0.80 | KDM4E (0.36) | POLBKMT2AKDM4ESMN1; SMN2LMNA | |
| SCHEMBL8931408 | 0.74 | TP53 (0.41) | MAPTKMT2ATP53MEN1PABPC1 | |
| SCHEMBL4870560 | 0.71 | LMNA (0.45) | MAPTKMT2AKDM4ETP53MEN1 | |
| SCHEMBL4867892 | 0.71 | TP53 (0.43) | MAPTPOLBKMT2ATP53MEN1 | |
| SCHEMBL30814349 | 0.68 | POLB (0.43) | MAPTPOLBKMT2ATP53MEN1 | |
| SCHEMBL1408334 | 0.68 | MAPT (0.58) | MAPTPOLBKMT2ATP53MEN1 | |
| SCHEMBL16879925 | 0.68 | METAP1 (0.40) | MAPTPOLBKMT2ATP53MEN1 | |
| SCHEMBL16879924 | 0.68 | MAPT (0.40) | MAPTPOLBKMT2ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332476-B2 | Pyridyl substituted ketolide antibiotics | NOVARTIS AG (CH) | 2008-02-19 | — | — | US | disclosed |
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | CHIRON CORPORATION (US) | 2005-01-13 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009764-A1 | Pyridyl substituted ketolide antibiotics | PKLR, KHK, PGD | MAPT 3247/4885POLB 1802/4885KMT2A 2250/4885 |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | MAPT 4688/4885POLB 3686/4885KMT2A 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.